See more : ProLight Opto Technology Corporation (5277.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of AEON Biopharma, Inc. (AEON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AEON Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hubtown Limited (HUBTOWN.BO) Income Statement Analysis – Financial Results
- Universus Photo Imagings Limited (UNIVPHOTO.NS) Income Statement Analysis – Financial Results
- Cascades Inc. (CAS.TO) Income Statement Analysis – Financial Results
- Vico International Holdings Limited (1621.HK) Income Statement Analysis – Financial Results
- Dividend Select 15 Corp. (DS.TO) Income Statement Analysis – Financial Results
AEON Biopharma, Inc. (AEON)
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.52M | 3.36M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 1.00K |
| Gross Profit | 0.00 | 0.00 | 2.52M | 3.36M |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 99.97% |
| Research & Development | 34.75M | 25.73M | 7.32M | 4.81M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.68M | 11.15M | 11.59M | 46.04M |
| Other Expenses | 0.00 | 10.21M | -5.61M | -10.75M |
| Operating Expenses | 48.43M | 36.88M | 18.91M | 51.73M |
| Cost & Expenses | 48.43M | 36.88M | 18.91M | 51.73M |
| Interest Income | 0.00 | 0.00 | 0.00 | 720.00K |
| Interest Expense | 0.00 | 0.00 | 15.00K | 7.47M |
| Depreciation & Amortization | 68.00K | 3.00K | -5.75M | 1.26M |
| EBITDA | -48.36M | -7.91M | -22.14M | -50.41M |
| EBITDA Ratio | 0.00% | 0.00% | -879.35% | -1,501.61% |
| Operating Income | -48.43M | -65.85M | -16.39M | -53.97M |
| Operating Income Ratio | 0.00% | 0.00% | -650.83% | -1,607.57% |
| Total Other Income/Expenses | -4.13M | 10.21M | -16.53M | 199.64M |
| Income Before Tax | -52.56M | -55.64M | -32.91M | 145.67M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,307.11% | 4,339.29% |
| Income Tax Expense | -160.49K | 28.97M | 15.00K | -14.65M |
| Net Income | -52.56M | -55.64M | -32.91M | 172.92M |
| Net Income Ratio | 0.00% | 0.00% | -1,307.11% | 5,151.03% |
| EPS | 0.00 | -2.53 | -2.22 | 11.69 |
| EPS Diluted | 0.00 | -2.53 | -2.22 | 11.69 |
| Weighted Avg Shares Out | 0.00 | 22.00M | 14.80M | 14.80M |
| Weighted Avg Shares Out (Dil) | 0.00 | 22.00M | 14.80M | 14.80M |
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth,...
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline Current cash and cash equivalents expected to be sufficient to support corporate operations into...
AEON Biopharma Reports First Quarter 2024 Financial Results
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AEON Biopharma Provides Update on Development Pipeline
Includes two late-stage clinical programs and two early-stage clinical programs Includes two late-stage clinical programs and two early-stage clinical programs
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that...
Source: https://incomestatements.info
Category: Stock Reports